default author photo

Clement Twumasi

University of Oxford

SCHOLARLY PAPERS

1

DOWNLOADS

492

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Safety, Tolerability, and Immunogenicity of NeomiVac, a Next-Generation mRNA–Lipid Nanoparticle Vaccine Comprising a Novel Ionisable Lipid: A First-In-Human, Phase 1, Dose-Escalation Trial

Number of pages: 1 Posted: 28 Jan 2026
University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford, University of Oxford, Neovac Ltd, Neovac Ltd, Neovac Ltd, Neovac Ltd, Neovac Ltd, Neovac Ltd, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, Neovac Ltd, Neovac Ltd, Neovac Ltd, Neovac Ltd, University of Oxford, University of Oxford - The Jenner Institute, Neovac Ltd, University of Oxford - Wellcome Trust Centre for Human Genetics, University of Oxford - Peter Medawar Building for Pathogen Research and University of Oxford - Oxford Vaccine Group
Downloads 492 (144,435)

Abstract:

Loading...

mRNA vaccine, novel lipid nanoparticle vaccine (LNP), reactogenicity, immunogenicity, SARS-CoV2